FDA, Wegovy and Novo Nordisk
Digest more
32m
Zacks.com on MSNNVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend.
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis but without cirrhosis.